Skip to main content
. 2015 Oct 14;195(10):4822–4831. doi: 10.4049/jimmunol.1501828

FIGURE 2.

FIGURE 2.

PRN694 inhibits TCR-induced cytokine production from human PBMCs and in mouse plasma. (A) Human PBMCs were stimulated in vitro with anti-CD3/CD28 for 18 h in the absence or presence of PRN694 at 20 nM or 5.0 μM, and levels of IFN-γ, IL-6, and IL-2 in the supernatants were measured as part of the human InflammationMAP v.1.0 biomarker panel. A complete list of all biomarkers of the panel is found in Supplemental Table I. Data are shown as means ± SEM (n = 3/group). (B) A dose response of PRN694 was used to assess the potency of inhibition of IL-2 production by PBMCs. Cells were stimulated with anti-CD3/CD28 (▪) or thapsigargin (▴). IL-2 was quantified using an AlphaLISA IL-2 immunoassay. (C) Mice were injected i.p. with PRN694 (20 mg/kg) followed by anti-CD3 (10 μg/mouse) 1 or 6 h later. Two hours after anti-CD3 injection, plasma was collected and cytokines were measured as part of the RodentMAP v.3.0 biomarker panel. A complete list of all biomarkers of the panel is found in Supplemental Table II. Dotted lines indicate the detection limit for each cytokine in the assay. Data are shown as means ± SEM (n = 3/group). *p < 0.05, **p < 0.01.